Molecular Partners
Update in progressMOLN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Molecular Partners AG is a Swiss clinical-stage biotechnology company that designs and develops designed ankyrin repeat proteins (DARPins) for oncology. Its pipeline includes MP0317 (Phase 2 solid tumors), MP053 (Phase 1 acute myeloid leukemia), MP0712 (212Pb Radio-DARPin targeting DLL3 for SCLC and neuroendocrine tumors), MP0726 (Radio-DARPin for ovarian and MSLN-expressing cancers), MP0621 (Switch-DARPin for conditioning), and a broader Radio-DARPin platform. Partners include Orano Med SAS and Eckert & Ziegler SE. Founded 2004, Schlieren, Switzerland.
Company score
- Sentiment
- 0.26
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!